Harnessing Biomaterials to Study and Direct Antigen-Specific Immunotherapy

ACS Appl Bio Mater. 2023 Jun 19;6(6):2017-2028. doi: 10.1021/acsabm.3c00136. Epub 2023 Apr 17.

Abstract

Immunotherapies are an evolving treatment paradigm for addressing cancer, autoimmunity, and infection. While exciting, most of the existing therapies are limited by their specificity─unable to differentiate between healthy and diseased cells at an antigen-specific level. Biomaterials are a powerful tool that enable the development of next-generation immunotherapies due to their tunable synthesis properties. Our lab harnesses biomaterials as tools to study antigen-specific immunity and as technologies to enable new therapeutic vaccines and immunotherapies to combat cancer, autoimmunity, and infections. Our efforts have spanned the study of intrinsic immune profiles of biomaterials, development of novel nanotechnologies assembled entirely from immune cues, manipulation of innate immune signaling, and advanced technologies to direct and control specialized immune niches such as skin and lymph nodes.

Keywords: autoimmunity; biomaterials; immune engineering; immunology; nanotechnology; vaccine.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Antigens
  • Biocompatible Materials* / chemistry
  • Biocompatible Materials* / therapeutic use
  • Humans
  • Immunotherapy
  • Neoplasms* / drug therapy
  • Signal Transduction

Substances

  • Biocompatible Materials
  • Antigens